C07C49/563

Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis

The present invention relates to the identification of provided cyclohexane-1,3-diones (CHD compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided CHD compounds.

SMALL MOLECULE ANTAGONISTS OF PF4

The present application provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Y, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are described herein. The methods of using these compounds to inhibit tetramerization of PF4 and to treat the associated diseases and conditions, such as heparin-induced thrombocytopenia and thrombosis (HITT) and vaccine-induced immune thrombotic thrombocytopenia (VITT), methods of making these compounds, and pharmaceutical compositions containing these compounds are also disclosed.

##STR00001##

SMALL MOLECULE ANTAGONISTS OF PF4

The present application provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Y, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are described herein. The methods of using these compounds to inhibit tetramerization of PF4 and to treat the associated diseases and conditions, such as heparin-induced thrombocytopenia and thrombosis (HITT) and vaccine-induced immune thrombotic thrombocytopenia (VITT), methods of making these compounds, and pharmaceutical compositions containing these compounds are also disclosed.

##STR00001##